Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture

NCT04432389 is registered in ClinicalTrials.gov with Bone Therapeutics S.A as lead sponsor.

NCT NCT04432389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04432389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture
Lead sponsor
Bone Therapeutics S.A
Phase
Phase 2
Overall status
Unknown status
Start date
January 8, 2021
Completion date
March 31, 2024
Enrollment
178 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

tibial fracture